Immunetrics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Immunetrics, Inc. - overview
Established
2001
Location
Pittsburgh, PA, US
Primary Industry
Software
About
Immunetrics, Inc. , located in Pittsburgh, US, specializes in providing advanced biopharmaceutical modeling and simulation solutions, supporting the pharmaceutical and biotechnology industries with innovative approaches to drug discovery and development. Founded in 2001 in Pittsburgh, US, Immunetrics, Inc. focuses on biopharmaceutical modeling solutions.
The company has undergone strategic changes, including its recent acquisition by Simulations Plus, Inc. on June 20, 2023, for USD 15. 5 mn, marking a significant shift in its operational strategy. The firm has been involved in a total of 3 deals, with its latest funding coming from a Trade Sale.
The CEO of Immunetrics is Steve Chang, with the founder being Mitchell Fink. Immunetrics offers a comprehensive suite of innovative software solutions and consulting services tailored for the pharmaceutical and biotechnology sectors. Core products include modeling and simulation software, which are essential tools in drug discovery and development processes. These solutions enable clients to simulate pharmacokinetics, predict drug absorption and metabolism, and assess potential toxicity.
With over 25 years of industry experience, Immunetrics serves a diverse client base, including major pharmaceutical companies and biotech firms across North America, Europe, and Asia. Immunetrics generates revenue primarily through the sale of software licenses and consulting services. The company employs a subscription-based model, allowing clients access to tailored software tools for drug development. Revenue is complemented by consulting services that offer expert support in quantitative systems pharmacology and pharmacokinetics/pharmacodynamics.
Key products contributing to revenue include flagship software tools, fostering long-term relationships with clients through annual subscriptions and consulting fees. Following its acquisition in June 2023, Immunetrics plans to enhance its research and development infrastructure, leveraging the resources provided by Simulations Plus, Inc. The company aims to introduce new software solutions aimed at improving drug development efficiencies, with timelines for product releases to be announced. Immunetrics is also targeting expansion into new geographic markets, specifically focusing on Europe and Asia, in the coming years.
The recent funding from the acquisition will be utilized to support these growth initiatives and strengthen operational capabilities.
Current Investors
Pittsburgh Life Sciences Greenhouse
Primary Industry
Software
Sub Industries
Bioinformatics, Pharmaceutical Research & Development, Medical Software, Analytics & Performance Software
Website
www.immunetrics.com
Verticals
Big Data, HealthTech
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Immunetrics, Inc. - employee data
Immunetrics, Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board Member | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.